Recent trends in the use of diabetes drugs GLP-1 receptor agonists and SGLT2 inhibitors among people with type 2 diabetes and heart artery disease in the USA

Prevalent use of GLP-1 receptor agonists and/or SGLT2 inhibitors increased from 9.2% in 2018 to 27.1% in 2022 among patients with type 2 diabetes and atherosclerotic cardiovascular disease.

• Eligible annual patient numbers for the study ranged from 279,474 to 348,997 during the analysis period.
• The use of GLP-1 receptor agonists alone rose from 5.2% to 9.9% between 2018 and 2022.
• Sodium-glucose cotransporter 2 inhibitor use alone increased from 2.8% to 12.2% over the same period.
• Incident use of GLP-1 receptor agonists and/or SGLT2 inhibitors following a new diagnosis of atherosclerotic cardiovascular disease grew from 5.9% to 17.0% from 2018 to 2022.
• For GLP-1 receptor agonists alone, incident use rose from 3.6% to 7.8%, while SGLT2 inhibitors alone increased from 1.8% to 7.0%.

Simplified